CPC A61K 35/745 (2013.01) [A23L 33/135 (2016.08); A23L 33/21 (2016.08); A61K 39/39 (2013.01); A61K 9/0053 (2013.01); A61K 9/14 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01)] | 20 Claims |
1. A method of treating a human subject, the method comprising administering to the subject an oral formulation comprising Bifidobacterium longum strain having the accession number NCIMB 41676 and an ingestible carrier, wherein the formulation improves or sustains vitality in the subject as measured by an increase in theta band resting state brain oscillations in the frontal and cingulate cortex and a decrease in beta-3 resting state brain oscillations in the hippocampus, fusiform, and temporal cortex.
|